Harmon Cyrus 4
4 · Olema Pharmaceuticals, Inc. · Filed May 7, 2024
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
2024-05-06$10.92/sh−5,000$54,600→ 806,283 total
Holdings
- 122,028(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
- [F2]The weighted average sale price for the transaction reported was $10.92, and the range of prices was between $10.91 and $10.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.